Clinical Trial Update: A Single Agent Phase II Study of Romidepsin (Depsipeptide, FK228) in the Treatment of Cutaneous T-cell Lymphoma (CTCL) [Phase 2]

View source ↗

Summary

Phase II study of single-agent romidepsin (FK228) in cutaneous T-cell lymphoma has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous T-cell Lymphoma

Drugs mentioned

• Romidepsin (romidepsin)

Snippet

Sponsor: Celgene | Conditions: Cutaneous T-cell Lymphoma | Phase 2 | Status: COMPLETED | Results posted: 2010-04-23